Satyajit Kosuri
Overview
Explore the profile of Satyajit Kosuri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Korotev S, Cheng J, Haribabu Y, Strauss J, Dominguez S, Koppayi A, et al.
Haematologica
. 2025 Feb;
PMID: 39945023
Germline loss of function (LoF) DDX41 variants predispose to late-onset hematopoietic malignancies (HMs), predominantly of myeloid lineage. Among 43 families with germline DDX41 LoF variants, bone marrow (BM) biopsies in...
2.
He G, Belmont E, Karrison T, Stock W, LaBelle J, Kosuri S, et al.
Ann Transl Med
. 2024 Jun;
12(3):49.
PMID: 38911560
Background: The somatic mutation of fms-like tyrosine kinase 3 () in acute myeloid leukemia (AML) is associated with increased risk of relapse and lower survival rates. FLT3i as maintenance after...
3.
Yates S, Cursio J, Artz A, Kordas K, Bishop M, Derman B, et al.
Blood Adv
. 2024 May;
8(14):3785-3797.
PMID: 38810262
The optimal means of assessing candidacy of older adults (≥65 years) for chimeric antigen receptor T-cell (CAR-T) therapy are unknown. We explored the role of a geriatric assessment (GA)-guided multidisciplinary...
4.
Roloff G, Kosuri S, Nawas M, DuVall A, Patel A, Riedell P, et al.
Haematologica
. 2024 Apr;
109(11):3739-3744.
PMID: 38618681
No abstract available.
5.
Madero-Marroquin R, Dworkin E, Weiner H, Saygin C, Nawas M, Drazer M, et al.
Leuk Lymphoma
. 2024 Mar;
65(6):864-867.
PMID: 38441062
No abstract available.
6.
Nawas M, Kosuri S
Blood Adv
. 2023 Dec;
8(3):553-561.
PMID: 38096805
TP 53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are among the most lethal malignancies, characterized by dismal outcomes with currently available therapies. Allogeneic hematopoietic cell transplantation (allo-HCT) is...
7.
Rojek A, Kline J, Feinberg N, Appelbaum D, Pu Y, Derman B, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Oct;
24(2):83-93.
PMID: 37827881
Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a standard of care in relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphomas (B-NHL) though the majority of recipients do not...
8.
Roloff G, Wen F, Ramsland A, Artz A, Kosuri S, Stock W, et al.
Haematologica
. 2023 Jan;
108(8):2234-2239.
PMID: 36655425
No abstract available.
9.
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
Saygin C, Roloff G, Hahn C, Chhetri R, Gill S, Elmariah H, et al.
Blood Adv
. 2022 Aug;
7(4):549-554.
PMID: 36001442
There is increasing recognition that pathogenic germ line variants drive the development of hematopoietic cancers in many individuals. Currently, patients with hereditary hematologic malignancies (HHMs) receive similar standard therapies and...
10.
Tran M, Hasan Y, Wang A, Yenice K, Partouche J, Stock W, et al.
Blood Adv
. 2022 Jul;
7(3):285-292.
PMID: 35851593
Relapse after allogeneic stem cell transplantation (allo-SCT) remains the primary cause of treatment failure. A second SCT can result in long-term survival in a subset of patients, but the relapse...